Goldman Sachs and Morgan Stanley are advising BD’s acquisition of Edwards Lifesciences’ Critical Care Product Group for $4.2 billion.
This move enhances BD’s portfolio with advanced patient monitoring technologies and AI-enabled clinical decision tools. BD, a global medical technology leader, has agreed to buy the Critical Care division from Edwards Lifesciences. Specializing in advanced monitoring solutions, this division includes innovations like